How long is it safe to take Wegovy, and what does the evidence say?

The myth worth clearing up first: 'you can just stop when you reach your target'

A lot of people starting Wegovy assume they'll take it for a few months, hit a goal weight, and come off it cleanly. That framing misunderstands how the medicine works. Semaglutide acts on the hormonal signals that regulate appetite; once those signals are no longer being modulated, appetite typically returns. Clinical trial data showed weight regain after stopping, which is why duration of treatment is a considered clinical decision rather than something tied to a number on the scales. The Wegovy overview covers how the medicine works in more detail, and it's worth reading before forming expectations about timelines.

The equally common myth in the other direction is that staying on it indefinitely is straightforwardly safe. Current NICE guidance for NHS patients caps recommended use at two years under TA875. Private prescribing follows the licensed indication rather than NICE's NHS-specific cost-effectiveness frame, but duration is still something a prescriber weighs up individually. Neither extreme (a quick course or an open-ended indefinite run without clinical review) reflects responsible use.

What the clinical evidence shows about long-term safety

The principal trial programme for Wegovy followed participants for 68 weeks at the 2.4mg maintenance dose, recording around 15% average weight reduction against placebo. If you want to see the underlying data, the STEP 1 trial, published in the New England Journal of Medicine, is the primary source. Longer-term cardiovascular outcome data (the SELECT trial) extends the evidence base further.

Across these studies, the side-effect profile was broadly consistent: gastrointestinal symptoms dominated (nausea, loose stools, constipation, reflux) and were most common in the early weeks of treatment and after dose increases. Most participants found them manageable and temporary. Serious adverse events were uncommon. Pancreatitis was identified as an infrequent but potentially serious risk; the MHRA issued a formal Drug Safety Update on this in January 2026, recommending that patients seek urgent help for severe persistent stomach pain, particularly if it spreads to the back. Gallbladder problems were also noted at a higher rate than placebo in longer trials.

If you are noticing new or worsening symptoms and want a sense of the broader picture before speaking to a clinician, the full Wegovy side effects page covers each category in context.

When to get medical help, and what not to ignore

If you're already on Wegovy and something feels off, you deserve a straight answer on what warrants a call versus what usually settles. Most of the early-stage nausea and stomach discomfort is expected and does not mean something is wrong. A good breakdown of how quickly effects typically appear is on the timing of Wegovy side effects page. Persisting through mild initial symptoms is normal; the following are not situations to wait out.

Seek urgent medical help if you experience: severe, persistent stomach pain (especially if it radiates to the back) with or without vomiting (this may indicate pancreatitis); signs of a serious allergic reaction such as swelling of the face, lips or throat, or difficulty breathing; jaundice or upper-right abdominal pain (gallbladder symptoms); signs of severe dehydration from prolonged vomiting or diarrhoea, including very dark urine or dizziness on standing; sudden changes in vision; or thoughts of self-harm or low mood that feel new or out of character.

Tell any healthcare professional treating you (including an anaesthetist before any procedure) that you are taking semaglutide, as it slows gastric emptying and this is clinically relevant. The safety overview for Wegovy goes into more detail on managing treatment safely day to day. Suspected side effects from any medicine, including ones already listed on the patient leaflet, can be reported via the MHRA's Yellow Card scheme.

How long you specifically should take it, and who decides that

If you're wondering whether to continue, pause or stop, that decision belongs with your prescriber, not a webpage. What we can say is that it is not a binary choice between stopping at two years and continuing forever: prescribers review whether benefits still outweigh risks, whether weight loss has been adequate, and whether any new health factors change the picture. The question of Wegovy's long-term safety profile is one our prescribers address regularly with patients at repeat review.

If you're weighing up Wegovy as a treatment option and want to understand costs alongside duration, the Wegovy cost page sets out what private treatment typically involves. And if you have general questions about the evidence and eligibility for weight-loss treatment more broadly, our treatment overview is a useful starting point.

At nume, our GPhC-registered prescribers discuss suitability, expected duration and side effects as a standard part of every consultation, not as a formality but because those conversations shape whether treatment actually works for you. If you'd like that review, start your free consultation and a prescriber will read your answers the same day.